494772-07-5

Basic information

• Product Name: 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine
• Synonyms: 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine;5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine 97%;5-bromo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine;5-Bromo-2-(tetrahydro-2H-pyran-4-yloxy)pyridine 97%;4-(5-Bromopyridin-2-yloxy)tetrahydro-2H-pyran;4-[(5-Bromopyridin-2-yl)oxy]tetrahydro-2H-pyran, 4-[(5-Bromopyridin-2-yl)oxy]oxane;5-Bromo-2-[(tetrahydro-2H-pyran-4-yl)oxy]pyridine97%
• CAS NO: 494772-07-5
• Molecular Formula: C10H12BrNO2
• Molecular Weight: 258.11178
• Mol File: 494772-07-5.mol

Chemical Properties

• Melting Point: 96-98
• Boiling Point: 320.2 °C at 760 mmHg
• Flash Point: 147.5 °C
• Appearance: /
• Density: 1.463 g/cm³
• Vapor Pressure: 0.000603mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: 2-8°C
• PKA: 1.30±0.22(Predicted)
• CAS DataBase Reference: 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine(494772-07-5)
• EPA Substance Registry System: 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine(494772-07-5)

Safety Data

• Hazardous Substances Data: 494772-07-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine is used as a reactant in the preparation of azole compounds, which are known for their anti-inflammatory properties. These azole compounds can be utilized in the treatment of various inflammatory diseases, making 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine a valuable starting material for the development of new therapeutic agents.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-Bromo-2-(tetrahydropyran-4-yloxy)pyridine can serve as a key intermediate for the synthesis of more complex molecules with potential applications in various industries. Its unique structural features allow for further functionalization and modification, making it a versatile building block for the creation of novel compounds with diverse properties and uses.

InChI:InChI=1/C10H12BrNO2/c11-8-1-2-10(12-7-8)14-9-3-5-13-6-4-9/h1-2,7,9H,3-6H2

Upstream product

• 27828-85-9 2H-pyran-4-ol 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 53939-30-3 5-bromo-2-chloropyridine 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 13466-38-1 5-bromopyridin-2(1H)-one 

Downstream Products

• 910036-98-5 2-((tetrahydro-2H-pyran-4-yl)oxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Relevant articles and documents

Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement

Optimization of a series of azabenzimidazoles identified from screening hit 2 and the information gained from a co-crystal structure of the azabenzimidazole-based lead 6 bound to CDK9 led to the discovery of azaindoles as highly potent and selective CDK9 inhibitors. With the goal of discovering a highly selective and potent CDK9 inhibitor administrated intravenously that would enable transient target engagement of CDK9 for the treatment of hematological malignancies, further optimization focusing on physicochemical and pharmacokinetic properties led to azaindoles 38 and 39. These compounds are highly potent and selective CDK9 inhibitors having short half-lives in rodents, suitable physical properties for intravenous administration, and the potential to achieve profound but transient inhibition of CDK9 in vivo.

AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS

The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.

NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF

The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of meta

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

New Positive allosteric modulators of nicotinic acetylcholine receptor

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS

The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.

CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR

Certain cycloalkyloxy- and heterocycloalkyloxypyridine compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.

NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES

The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.